Regulation of circulating sclerostin levels by sex steroids in women and in men

Abstract

Sex steroids are important regulators of bone turnover, but the mechanisms of their effects on bone remain unclear. Sclerostin is an inhibitor of Wnt signaling, and circulating estrogen (E) levels are inversely associated with sclerostin levels in postmenopausal women. To directly test for sex steroid regulation of sclerostin levels, we examined effects of E treatment of postmenopausal women or selective withdrawal of E versus testosterone (T) in elderly men on circulating sclerostin levels. E treatment of postmenopausal women (n = 17) for 4 weeks led to a 27% decrease in serum sclerostin levels [versus +1% in controls (n = 18), p < .001]. Similarly, in 59 elderly men, we eliminated endogenous E and T production and studied them under conditions of physiologic T and E replacement, and then following withdrawal of T or E, we found that E, but not T, prevented increases in sclerostin levels following induction of sex steroid deficiency. In both sexes, changes in sclerostin levels correlated with changes in bone-resorption, but not bone-formation, markers (r = 0.62, p < .001, and r = 0.33, p = .009, for correlations with changes in serum C-terminal telopeptide of type 1 collagen in the women and men, respectively). Our studies thus establish that in humans, circulating sclerostin levels are reduced by E but not by T. Moreover, consistent with recent data indicating important effects of Wnts on osteoclastic cells, our findings suggest that in humans, changes in sclerostin production may contribute to effects of E on bone resorption. © 2011 American Society for Bone and Mineral Research.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 38

1. 1.

   Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.

   Not in our library10.7326/0003-4819-117-1-1

2. 2.

   Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.

   Not in our library10.1210/edrv.23.3.0465

3. 3.

   Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. J Clin Invest. 1998;101:1942-1950.

   Not in our library10.1172/jci1039

4. 4.

   Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL. Effect of blockade of TNF-α and interleukin 1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007;22:724-729.

   Not in our library10.1359/jbmr.070207

5. 5.

   Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13:1124-1133.

   Not in our library10.1359/jbmr.1998.13.7.1124

6. 6.

   Lean JM, Chow JW, Chambers TJ. The rate of cancellous bone formation falls immediately after ovariectomy in the rat. J Endocrinol. 1994;142:119-125.

   Not in our library10.1677/joe.0.1420119

7. 7.

   Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.

   Not in our library10.1210/edrv.21.2.0395

8. 8.

   Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553-1560.

   Not in our library10.1172/jci10942

9. 9.

   Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003;88:204-210.

   Not in our library10.1210/jc.2002-021036

10. 10.

    Sanyal A, Hoey KA, Modder UI, et al. Regulation of bone turnover by sex steroids in men. J Bone Miner Res. 2008;23:705-714.

    Not in our library10.1359/jbmr.071212

11. 11.

    Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643.

    Not in our library10.1210/en.2007-0270

12. 12.

    Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209.

    Not in our library10.1172/jci28551

13. 13.

    Armstrong VJ, Muzylak M, Sunters A, et al. WNT/B-Catenin signaling is a component of osteoblastic bone cells' early responses to load-bearing, and requires estrogen receptor a. J Biol Chem. 2007;282:20715-20727.

    Not in our library10.1074/jbc.m703224200

14. 14.

    Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.

    Not in our library10.1086/318811

15. 15.

    Balemans W, Ebeling M, Patel N, et al. Increase bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543.

    Not in our library10.1093/hmg/10.5.537

16. 16.

    Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144-152.

    Not in our library10.1002/ajmg.10401

17. 17.

    Balemans W, Patel N, Ebeling M, et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97.

    Not in our library10.1136/jmg.39.2.91

18. 18.

    Li X, Ominsky MS, Niu Q-T, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.

    Not in our library10.1359/jbmr.080216

19. 19.

    Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-588.

    Not in our library10.1359/jbmr.081206

20. 20.

    Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95:1991-1997.

    Not in our library10.1210/jc.2009-2283

21. 21.

    Clowes JA, Eghbali-Fatourechi GZ, McCready L, Oursler MJ, Khosla S, Riggs BL. Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int. 2009;20:761-769.

    Not in our library10.1007/s00198-008-0731-y

22. 22.

    Terpos E, Christoulas D, Katodritou E, et al. High serum sclerostin correlates with advanced stage, increased bone resorption, reducted osteoblast function, and poor survival in newly-diagnosed patients with multiple myeloma. Blood. 2009;114.

    Not in our library

23. 23.

    Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764.

    Not in our library10.1016/j.devcel.2005.02.017

24. 24.

    Huang Q-Y, Li GHY, Kung AWC. The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone. 2009;45:289-294.

    Not in our library10.1016/j.bone.2009.03.676

25. 25.

    Boruk M, Savory JG, Hache RJ. AF-2-dependent potentiation of CCAAT enhancer binding protein beta-mediated transcriptional activation by glucocorticoid receptor. Mol Endocrinol. 1998;12:1749-1763.

    Not in our library10.1210/mend.12.11.0191

26. 26.

    Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005;102:11651-11656.

    Not in our library10.1073/pnas.0505575102

27. 27.

    Carroll JS, Liu S, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33-43.

    Not in our library10.1016/j.cell.2005.05.008

28. 28.

    Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061.

    Not in our library10.1056/nejm199410203311604

29. 29.

    Smith EP, Specker B, Bachrach BE, et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab. 2008;93:3088-3096.

    Not in our library10.1210/jc.2007-2397

30. 30.

    Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337:91-95.

    Not in our library10.1056/nejm199707103370204

31. 31.

    Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 1998;339:599-603.

    Not in our library10.1056/nejm199808273390905

32. 32.

    Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005;328:688-696.

    Not in our library10.1016/j.bbrc.2004.11.097

33. 33.

    Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056-5062.

    Not in our library10.1210/jc.2010-0720

34. 34.

    Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. American Society for Bone and Mineral Research Annual Meeting. 2007.

    Not in our library

35. 35.

    Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-192.

    Not in our library10.1210/er.2007-0014

36. 36.

    Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119:1283-1296.

    Not in our library10.1242/jcs.02883

37. 37.

    Modarresi R, Xiang Z, Yin M, Laurence J. WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol. 2009;174:123-135.

    Not in our library10.2353/ajpath.2009.080484

38. 38.

    Qiang Y-W, Chen Y, Brown N, et al. Characterization of Wnt/beta-catenin signaling in osteoclasts in multiple myeloma. Br J Haematol. 2009;148:726-738.

    Not in our library10.1111/j.1365-2141.2009.08009.x

Cited by papers we hold 4

• Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches · 2023
  No notice
• Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway · 2011
  No notice
• Relation of age, gender, and bone mass to circulating sclerostin levels in women and men · 2010
  No notice
• The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: Is a revision needed? · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.